Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response.

DES PLAINES, Illinois, March 7 /PRNewswire/ --

- Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer

Abbott (NYSE: ABT) today announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) (erlotinib), an oral tablet indicated for the treatment of patients with locally advanced or metastatic ...

Read the rest of this article with a Free Trial at HighBeam Research.